Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neuroblastoma 1Myeloproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Hematologic Diseases 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Rituximab 70Cyclophosphamide 46fludarabine 21fludarabine phosphate 20Mycophenolic Acid 20Etoposide 18Whole-Body Irradiation 17Filgrastim 15Radiotherapy 14Antilymphocyte Serum 14Tacrolimus 13Melphalan 13Gemcitabine 13Cyclosporine 13Busulfan 13Methotrexate 12Lenalidomide 12Bortezomib 12Bendamustine Hydrochloride 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10Cytarabine 10Doxorubicin 8Dexamethasone 8venetoclax 7thymoglobulin 7pembrolizumab 7Thiotepa 7Methylprednisolone 7Granulocyte Colony-Stimulating Factor 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, Non-Hodgkin × RG7388 × Clear all
NCT02624986 2020-05-18

A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants

Hoffmann-La Roche

Phase 1/2 Terminated
25 enrolled 21 charts
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡